Filing Flows › ImmunityBio (IBRX) › Q1 2026 › vs Q1 2025
ImmunityBio (IBRX) Q1 2026 vs Q1 2025 (year over year)
ImmunityBio's revenue rose $27.7M (+168%) from $16.5M in Q1 2025 to $44.2M in Q1 2026. The biggest changes: Product revenue, net +$27.7M (+168%); Other revenues +$31K (+388%).
ImmunityBio, Q1 2026: revenue $44.2M (+168% year over year), operating margin -157.9%, net loss $633M, operating cash flow −$75.4M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $44.2M | $16.5M | $27.7M | +168% |
| Other revenues | $39K | $8K | $31K | +388% |
| Revenue | $44.2M | $16.5M | $27.7M | +168% |
| Net loss | $633M | $130M | $503M | +388% |
| Costs & expenses | $677M | $146M | $531M | +362% |
| Operating costs | $114M | $80.9M | $33.1M | +41% |
| Interest & other, net | $563M | $65.5M | $498M | +760% |
| Income tax | $9K | −$234K | $243K | — |
| Cost of revenue | $238K | $58K | $180K | +310% |
| Other operating costs | $114M | $80.9M | $32.9M | +41% |
| Operating cash sources | $633M | $130M | $503M | +388% |
| Depreciation & amortization | $4.4M | $3.8M | $551K | +14% |
| Share-based compensation | $8.2M | $9.5M | −$1.4M | -14% |
| Working capital & other | $545M | $30.4M | $514M | 18× |
| Cash used in operations | $75.4M | $85.9M | −$10.5M | -12% |
| Net loss absorbed | $633M | $130M | $503M | +388% |
Questions
How much did ImmunityBio's revenue grow year over year in Q1 2026?
ImmunityBio's revenue rose $27.7M (+168%) from $16.5M in Q1 2025 to $44.2M in Q1 2026.
What drove ImmunityBio's revenue change in Q1 2026?
Product revenue, net +$27.7M (+168%); Other revenues +$31K (+388%).